Human papillomavirus (HPV) vaccination in Japan

Abstract

AbstractAimTo review the status of human papillomavirus (HPV) vaccination in Japan from inception to the present, focusing on past and current challenges.MethodsPublished articles and website content related to HPV vaccination were reviewed.ResultsThe Ministry of Health, Labor and Welfare suspended proactive recommendations for HPV vaccination in June 2013 following repeated media reports of girls experiencing adverse events, including chronic pain and walking disturbances, after receiving the HPV vaccine. Despite later recognition of these symptoms as a functional somatic syndrome, HPV vaccine coverage of target girls aged 12 to 16 years in the National Immunization Program (NIP) rapidly decreased to near zero. This suspension of the proactive HPV vaccination recommendation ceased in fiscal year (f‐year) 2022, initiating a 3‐year catch‐up free HPV vaccination period from April 2022 to March 2025 for women born from f‐years 1997 to 2005. These drastic changes were driven by established evidence of the effectiveness and safety of HPV vaccines reported from both Japan and other countries, and a nine‐valent HPV vaccine has been included in the NIP since f‐year 2023. However, the estimated HPV vaccination rate in the NIP remains low at ≤30%.ConclusionsTo regain high coverage of HPV vaccination in Japan, it is essential that government, industry, and academic society work together to raise awareness and educate Japanese people about cervical cancer prevention and HPV‐related diseases.